SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

345 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-12-31

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892

Bronchiectasis

RECRUITING PHASE3

Efficacy and Safety of AG2001 in Patients With Acute Bronchitis

NCT07198347

Acute Bronchitis

NOT_YET_RECRUITING PHASE3

A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis

NCT00769119

Bronchiectasis

COMPLETED PHASE2

Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients

NCT01917643

COPD Exacerbation

COMPLETED

A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis

NCT07201051

Bronchiectasis

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Bronchitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Moxifloxacin (Avelox, BAY12-8039)

Intervention Type DRUG

Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Moxifloxacin (Avelox, BAY12-8039)

Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute exacerbation of chronic bronchitis from Anthonisen type I or II
* FEV1 of \< 50 %
* Patient must be ensured in the statutory health insurance
* Further contraindications of the prescribed pharmaceutical products must be considered